Press Releases
This section of Viatris.com contains information that may not be suitable for use in all countries due to varied regulatory requirements, data protection requirements and practices or medical practices, and distinctions among product approval and commercial availability. The information contained in each news release or statement posted on this page is presented as of the date it was issued. The company undertakes no obligation to update the information for changes or subsequent events after the date it was originally issued.
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Jan 3, 2023
- Dec 29, 2022
- Dec 23, 2022
- Dec 14, 2022
- Dec 14, 2022
- Nov 29, 2022
- Nov 18, 2022
- Nov 10, 2022
- Nov 7, 2022
- Nov 7, 2022
- Oct 25, 2022
- Oct 24, 2022
- Oct 11, 2022
- Sep 6, 2022
- Aug 8, 2022
- Jul 5, 2022
- Jul 1, 2022
- May 20, 2022
- May 19, 2022
- May 16, 2022
- May 9, 2022
- Apr 12, 2022
- Apr 8, 2022
- Mar 30, 2022
- Mar 17, 2022
- Mar 16, 2022
- Mar 1, 2022
- Feb 28, 2022
- Feb 4, 2022
- Feb 3, 2022Approval Reinforces Viatris' Steadfast Commitment to Breaking Down Barriers and Expanding Access to Complex Generic Products
- Jan 18, 2022
- Jan 6, 2022
- Dec 29, 2021Decisions reaffirm Viatris' ability to provide patient access to interchangeable Semglee®
- Dec 17, 2021
- Dec 6, 2021
- Dec 1, 2021
- Nov 18, 2021
- Nov 16, 2021Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
- Nov 11, 2021The multi-year impact investment will rebuild homes for at least 50 veterans
- Nov 8, 2021Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share
- Oct 20, 2021Upcoming launch of two interchangeable biosimilar insulin glargine injection options co-developed with Biocon Biologics will help increase access to critical treatment for millions of Americans living with diabetes
- Oct 13, 2021
- Oct 11, 2021Fortune Recognizes Viatris for Expanding Access to Innovative HIV Medicines, Particularly in Low- and Middle-income Countries
- Aug 30, 2021
- Aug 30, 2021
- Aug 9, 2021Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share
- Jul 28, 2021Interchangeable Designation Allows Substitution at the Pharmacy Counter for Lantus® Across the U.S. to Help Increase Access to Medicines for People Living with Diabetes
- Jul 27, 2021
- Jul 8, 2021
- Jun 23, 2021Company Confident Evidence Regarding Only Remaining Claim Will Show Mylan's Actions Were Lawful and Pro-competitive
